Plasma kynurenines and prognosis in patients with heart failure

Anders Lund1,*, Jan Erik Nordrehaug1,2, Grete Slettom1,3, Stein-Erik Hafstad Solvang1,4, Eva Kristine Ringdal Pedersen1,3, Øivind Midttun5, Arve Ulvik5, Per Magne Ueland1,6, Ottar Nygård1,3, Lasse Melvaer Giil1,4

1 Department of Clinical Science, University of Bergen, Bergen, Norway, 2 Department of Cardiology, Stavanger University Hospital, Stavanger, Norway, 3 Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, 4 Department of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway, 5 Bevital AS, Bergen, Norway, 6 Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway

* lund.anders88@gmail.com

Abstract

Background
Metabolites of the kynurenine pathway (mKP) relate to important aspects of heart failure pathophysiology, such as inflammation, energy-homeostasis, apoptosis, and oxidative stress. We aimed to investigate whether mKP predict mortality in patients with heart failure.

Methods
The study included 202 patients with heart failure (73.8% with coronary artery disease (CAD)), propensity score matched to 384 controls without heart disease, and 807 controls with CAD (71%). All underwent coronary angiography and ventriculography at baseline. Plasma mKP, pyridoxal 5’phosphate (PLP) and CRP were measured at baseline. Case-control differences were assessed by logistic regression and survival by Cox regression, adjusted for age, gender, smoking, diabetes, ejection fraction, PLP, eGFR and CRP. Effect measures are reported per standard deviation increments.

Results
Higher plasma levels of kynurenine, 3- hydroxykynurenine (HK), quinolinic acid (QA), the kynurenine-tryptophan-ratio (KTR) and the ratio of HK to xanthurenic acid (HK/XA) were detected in heart failure compared to both control groups. The mortality rate per 1000 person-years was 55.5 in patients with heart failure, 14.6 in controls without heart disease, and 22.2 in CAD controls. QA [HR 1.80, p = 0.013], HK [HR 1.77, p = 0.005], HK/XA [HR 1.67, p < 0.001] and KTR [HR 1.55, p = 0.009] were associated with increased mortality in patients with heart failure, while XA [HR 0.68–0.80, p = 0.013–0.037] were associated with lower mortality in all groups. HK and HK/XA had weak associations with increased mortality in CAD-controls.
Conclusion
Elevated plasma levels of mKP and metabolite ratios are associated with increased mortality, independent of CAD, in patients with heart failure.

Introduction
Heart failure is associated with chronic inflammation, oxidative stress and cell-death, reflected by an increase in relevant biomarkers [1–3]. Recruitment and activation of monocytes in the myocardium is considered a key pathophysiological process. Activated monocytes and macrophages, stimulate myocardial fibrosis [4] and generate metabolites of the kynurenine pathway (mKP) from the essential amino acid tryptophan. mKP may mediate immunomodulation, antioxidant defence and apoptosis [5], which are considered pathogenic features in the development of heart failure.

Fig 1 illustrates the kynurenine pathway (KP). Glucocorticoids and cytokines induce the rate-limiting enzymes tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) who converts tryptophan (Trp) to kynurenine (Kyn) [6]. Interferon gamma (IFN-γ) activates the enzymes IDO and KMO [5]. Consequently, an increase in IFN-γ activity in patients with heart failure [7], may potentially result in elevated circulating levels of mKP.

Plasma levels of mKP predict prognosis in both healthy populations and in patients with cardiovascular disease. In a community-based cohort [8], mKP levels predicted all-cause mortality and cardiovascular mortality. In patients with stable angina pectoris and coronary artery disease (CAD), mKP predicted incident myocardial infarction [9]. The levels of the metabolite Kyn were increased in heart failure compared to controls [10]. In the same study, Kyn was associated with increased mortality, but other mKP were not measured [10]. CAD is frequent in patients with heart failure, and mKP have been hypothesized as a driver of CAD itself [8].

In this study, we aimed to investigate if Trp and mKP predict all-cause mortality in patients with established heart failure, compared to 2 control groups without heart failure, but with or without CAD.

Methods
Study participants
Patients were recruited from the Western Norway Coronary Angiography Cohort (WECAC) between 1999–2004. All patients (N = 4164) underwent elective coronary angiography at Haukeland- or Stavanger University Hospital mostly due to chest pain. Heart failure was identified in 202 patients. Two control groups were matched to these patients (as described below).

Patient characteristics were obtained at baseline. This included a medical history, self-administered questionnaires, a review of hospital records, and a clinical examination. A trained cardiologist performed cardiac catheterization. Significant coronary stenoses were confirmed in orthogonal views. The number of significantly stenosed vessels defined the severity of CAD (0 to 3). A stenosis in the left main stem counted as a two-vessel disease. Left ventricular ejection fraction (EF) was determined by ventriculography.

Self-report, a fasting glucose ≥ 7.0 mmol/L or non-fasting glucose > 11.1 mmol/L defined diabetes. Self-report and a serum cotinine level ≥ 85 nmol/L defined smoking status [11]. Blood samples were drawn at baseline. All-cause mortality was registered from The Norwegian
In this study, the kynurenine pathway (KP) is the major route of Trp degradation. The first step is the formation of formylkynurenine from Trp, catalysed by hepatic tryptophan 2,3-dioxygenase (TDO), predominantly expressed in the liver, or indoleamine-2,3-dioxygenase (IDO), expressed in monocytes. Formylkynurenine is rapidly converted to kynurenine (Kyn). Kyn is then converted to a variety of metabolites, many of which have immunomodulatory effects. These include 3-hydroxykynurenine (HK, formed by the flavin adenine dinucleotide (FAD)-dependent kynurenine monooxygenase (KMO)), kynurenic acid (KA) and xanthurenic acid (XA) (products of the pyridoxal 5-phosphate (PLP)-dependent kynurenine aminotransferase (KAT)), anthranilic acid (AA) and 3-hydroxyanthranilic acid (HAA) (products of the pyridoxal 5-phosphate (PLP)-dependent kynureninase (KNU)). HAA is further fully oxidized and in the process produce picolinic acid (not shown in figure) or converted to quinolinic acid (QA) in several steps and further to nicotinic acid mononucleotide and ultimately to NAD+.

Abbreviations: KP, kynurenine pathway; AA, anthranilic acid; FAD, flavin adenine dinucleotide; HAA, 3-hydroxyanthranilic acid; HAAO, 3-hydroxyanthranilate 3,4-dioxygenase; HK, 3-hydroxykynurenine; IDO, indoleamine (2,3)-dioxygenase; KA, kynurenic acid; KAT, kynurenine aminotransferase; KMO, kynurenine 3-monooxygenase; Kyn, kynurenine; KNU, kynureninase; PLP, pyridoxal 5´-phosphate; TDO, tryptophan (2,3)-dioxygenase; Trp, tryptophan; QA, quinolinic acid; QPRT, quinolinate phosphoribosyltransferase; XA, xanthurenic acid; NAM, nicotinamide; NAD, nicotinamide adenine dinucleotide.

https://doi.org/10.1371/journal.pone.0227365.g001

Cause of Death Registry, which covers 98% of the Norwegian population [12]. The censoring date in this study, 31.12.2013, was the time of the last link between the study and the registry.

Case definitions and propensity score matching

Heart failure was diagnosed in patients with symptoms, or on treatment, with a left ventricular ejection fraction (LVEF) ≤ 40% or LVEF < 50% and New York Heart Association (NYHA) class ≥ 2, resulting in 202 patients with heart failure. One-hundred and forty-one (69.8%) patients reported a diagnosis of heart failure. Renin-angiotensin inhibitors were used by 155 (76.7%), beta-blockers by 147 (72.8%), loop diuretics by 121 (59.9%) and 187 (92.5%) used either. Exclusion criteria were severe pulmonary disease, known cancer at baseline, dialysis-demanding renal failure and other terminal illness.

Two control groups were generated by three steps. First, patients from WECAC without criteria for heart failure, self-reported heart failure, and who were not on loop diuretics were considered potential controls. Second, cases with missing data (< 5%) were removed. This left 3425 potential controls. From these potential controls one subgroup was generated without
CAD (NCAD-C), based on no significant stenoses on coronary angiography and no previous myocardial infarction. All potential controls were matched to the heart failure group on age, gender, the severity of CAD, and/or previous myocardial infarction using propensity score matching, generating a control group with proportional CAD to the HF group (CAD-C). The subgroup without CAD was matched to the heart failure group on age and gender, again using propensity score matching, generating CAD-free controls (NCAD-C).

Fig 2. Propensity score matching of cases and controls. 3425 patients were identified as potential controls, who did not meet criteria for heart failure and did not report having a diagnosis of heart failure and did not use loop diuretics. These potential controls were propensity score matched to the heart failure group based on age, gender, number of vessels affected by CAD and prior MI generating controls with similar levels of CAD as the heart failure group (CAD-C). A subgroup of the potential controls without CAD and prior MI were propensity score matched based on age and gender, generating a control group without CAD (NCAD-C). Abbreviations: CAD, coronary artery disease represented by number of vessels affected by significant coronary artery stenosis on coronary angiography; MI, myocardial infarction; WECAC, western norway coronary angiography cohort; CAD-C coronary artery disease controls; NCAD-C, non-coronary artery disease controls.

https://doi.org/10.1371/journal.pone.0227365.g002

Ethics
This study was approved by the Regional Ethics Committee (REC) West, University of Bergen, Faculty of Medicine, Bergen, Norway, with identification number 2013/2022. All patients provided written consent after the study procedures had been explained in detail.

Measurements of metabolites and biomarkers
Blood samples were collected in tubes containing ethylenediamine tetraacetic acid (EDTA) from non-fasting participants. Trp, Kyn, 3-hydroxykynurenine (HK), kynurenic acid (KA), anthranilic acid (AA), 3-hydroxyanthranilic acid (HAA), xanthurenic acid (XA), quinolinic acid (QA), and PLP were measured by Bevital AS (http://www.bevital.no) using liquid
chromatography-tandem mass spectrometry (LC-MS/MS) assay [14]. The Kyn to Trp ratio (KTR) was calculated as Kyn (in nmol/L) divided by Trp (in μmol/L), as was the ratio of HK to XA (HK/XA).

Serum C-reactive protein (CRP) was measured using an ultrasensitive immunoassay by the Behring nephelometer II system (N Latex CRP mono, Behring Diagnostics, Marburg, Germany). Creatinine was measured by the hospital laboratories. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.

**Missing data**

Fifty-four patients did not have measurements of QA in the heart failure group. These missing data could be predicted from the independent variables ($X^2 20.3, p = 0.009$, Little’s test). The missing data for QA were imputed by multiple imputation. The strongest independent predictors of QA, Kyn, and HK were used for imputation together with age, gender, current smoking (estimated from cotinine [11]), eGFR, EF, PLP, CRP, and diabetes. The missing data were imputed 200 times and pooled estimates for all imputations are reported for QA [15].

**Statistics**

T-tests, Mann Whitney U-test, Chi-square, and log-rank tests were used for univariate analysis. Variables with non-normal distributions were transformed prior to multivariate analyses, according to Tukey’s ladder of powers (square root, logarithms, 1/square root, and inverse). All variables were subsequently standardized to their respective z-scores, calculated as $z = (x– \mu) / \sigma$, where $x$ is the variable, $\mu$ its mean and $\sigma$ its standard deviation. Each resulting data-point is then scaled to reflect the number of standard deviations it lies from a mean of zero. The aim of standardization was to make effect sizes of variables on different scales and transformations more comparable.

Metabolites were analyzed in separate multivariate models to avoid collinearity. We used logistic regression to estimate the differences between cases and controls, adjusted for potential confounders (CRP, diabetes, eGFR, PLP and Trp). From the significant models in logistic regression, we wanted to evaluate if kynurenines could be used as diagnostic biomarkers of heart failure. We evaluated metabolites and derived ratios separately. Using Lasso with all significant metabolites identified, or ratios, we identified the optimal multivariate logistic regression model using the default cross-validation method to identify $\lambda$. From this model, the predicted probabilities from the logistic regressions were used as the predictor of the diagnostic categories using receiver operating characteristic (ROC) analysis, which were presented graphically. The area under the curve (AUC) was estimated. We also estimated sensitivity and specificity directly from the logistic regression models using the post-hoc analysis tool “estat class” in Stata 16.

The hazard for all-cause mortality associated with metabolite levels was estimated using Cox proportional hazard analysis for patients with heart failure and the two control groups (CAD-C and NCAD-C). These analyses were adjusted for age, gender, CRP, diabetes, current smoking, eGFR, PLP, and Trp. The assumption of proportional hazards was checked in stratified analyses for categorical variables. For continuous variables, it was evaluated by inspecting Shoenfeld residuals and by performing the Therneau and Grambsch test.

The Benjamini-Hochberg procedure was used to adjust for multiple comparisons, at a false discovery rate (FDR) of 0.05 and FDR-adjusted p-values are reported (Q-values). The number of tests were estimated by summarizing all case-control comparisons and the hypotheses of association with mortality for the heart failure group. Statistical analyses and corresponding
graphs were conducted with Stata 15 and 16 (Stata Statistical Software: Release 15 and 16. College Station, TX: StataCorp LLC), R version 3.3.2 (packages: PM Match and p.adjust).

Confounders

The potential confounders eGFR, Trp, diabetes, PLP and CRP were selected \textit{a priori} and included in the multivariate models [16], as the primary aim was to identify independent associations with mKP and end points. Both renal function and protein intake could be reduced in heart failure [17, 18]. Plasma levels of mKP are strongly related to renal function [19, 20], and availability of the substrate Trp is linked to protein intake and downstream levels [21]. Trp was not included as a confounder when KTR was evaluated, as KTR is a product of Trp and Kyn. Patients with diabetes have higher levels of mKP and diabetes is an individual predictor for heart failure [22, 23]. PLP is an essential co-factor for KAT and KYNU [20], and have been found to be related to plasma levels of several mKP [24]. Elevated CRP is associated with a diagnosis of heart failure and increased mortality in heart failure [25]. CRP is an unspecific marker of systemic inflammation and could thus be indirectly associated with IDO-activation [26], supported by association with plasma levels of several mKP [27].

Results

Characteristics of the study participants

Table 1 summarizes group characteristics. Compared with both control groups, patients with heart failure had lower eGFR, higher CRP, and a higher prevalence of diabetes. PLP levels were lower in patients with heart failure compared to the NCAD-C group. The heart failure and both control groups were well matched for age and gender. The CAD-C group was, in addition, well matched on previous MI and number of vessels with coronary artery stenosis. Among the patients with open coronary arteries at baseline, there were higher prevalence of previous myocardial infarction and/or percutaneous coronary intervention in the CAD-C group compared to patients with heart failure.

Metabolites of the kynurenine pathway in patients with heart failure and control groups

Unadjusted plasma levels of Kyn, HK, KA, AA, HAA, QA, KTR, and HK/XA were higher in patients with heart failure compared to both control groups (S1 Table). Adjusted for confounders and multiple comparisons, patients with heart failure had higher levels of Kyn, HK, QA, KTR, and HK/XA ratio compared to both control groups (Table 2). From the metabolites, we identified a model with Trp and Kyn (and HK in CAD-C group) and both KTR and HK/XA, using Lasso. ROC curves from multivariate logistic regression gave an AUC of 0.7 for Trp and Kyn and an AUC of 0.69 for KTR and HK/XA with HF versus NCAD-C as outcome, and an AUC of 0.69 for Trp, Kyn and HK, and an AUC of 0.65 with HF versus CAD-C as outcome. Further, adding these kynurenines to models with confounders have only minimal improvement in AUC (See S1 and S2 Figs in supporting material).

Metabolites of the kynurenine pathway and all-cause mortality

Mortality differed significantly between the heart failure (46.5% died), NCAD-C (14.6%) and CAD-C (22.3%) groups. The median follow-up time was similar (9.6 years in heart failure, 10
The mortality rate per 1000 person-years was 55.5 in patients with heart failure, 14.6 in CAD controls and 22.2 in NCAD controls (Table 1).

In patients with heart failure, HK, QA, KTR and the HK/XA ratio were associated with increased risk of all-cause mortality, whereas XA was associated with a lower risk of all-cause mortality in all three groups. HK and the HK/XA ratio had a weaker association with mortality in the CAD-C group. Kyn, QA, and KTR were not associated with mortality in the control groups (Table 3). Fig 3 illustrate the strongest associations identified in adjusted analyses using Cox regression. Of note, the co-factor PLP was not associated with mortality (HR 0.90–1.06, p 0.209–0.706) in either group.
Table 2. Tryptophan and metabolites of the kynurenine pathway in heart failure. Adjusted analyses *.

|        | HF versus NCAD-C b |        | HF versus CAD-C c |
|--------|-------------------|--------|-------------------|
|        | OR 95% CI p Q d   | OR 95% CI p Q d   |        |
| Trp    | 1.08 0.89–1.31 .44 .53 1.22 1.04–1.45 .017* .034* |
| Kyn    | 1.94 1.47–2.56 <.001** 1.69 1.35–2.11 <.001** <.001** |
| HK     | 1.50 1.13–2.00 .005* .014* 1.46 1.16–1.85 .001* .005* |
| KA     | 1.15 0.90–1.48 .26 .36 1.11 0.90–1.37 .31 .40 |
| XA     | 0.90 0.72–1.14 .40 .50 0.96 0.79–1.17 .71 .71 |
| AA     | 1.16 0.94–1.45 .16 .25 1.05 0.87–1.26 .62 .64 |
| HAA    | 1.07 0.87–1.33 .52 .59 0.89 0.74–1.08 .23 .35 |
| QA     | 1.54 1.18–2.01 .002* .007* 1.44 1.15–1.79 .001* .005* |
| KTR    | 1.72 1.31–2.26 <.001** .001* 1.41 1.14–1.74 .001* .005* |
| HK/XA  | 1.30 1.04–1.64 .024* .045* 1.42 1.16–1.73 .001* .005* |

Case-control differences evaluated by logistic regression. Abbreviations: AA, anthranilic acid; CI, confidence interval; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; HK/XA, 3-hydroxykynurenine-xanthurenic acid ratio; KA, kynurenic acid; KTR, kynurenine-tryptophan ratio; Kyn, kynurenine; OR, odds ratio; SD; standard deviation; QA, quinolinic acid; XA, xanthurenic acid.

a Odds ratios per 1 SD of the predictor by logistic regression.
b Heart failure (HF, N = 202) vs controls without coronary artery disease (NCAD-C, N = 384) as outcome, adjusted for diabetes, glomerular filtration rate, pyridoxal 5’phosphate, C-reactive protein and Trp (not Trp in KTR model).
c HF (N = 202) vs controls with coronary artery disease (CAD-C, N = 807). Covariates as in model b.
d p-value adjusted for multiple comparisons in the study (Benjamini-Hochberg; 0.05)

https://doi.org/10.1371/journal.pone.0227365.t002

Table 3. Tryptophan, kynurenines and mortality in cases and controls *.

|        | Heart Failure | NCAD-C | CAD-C |
|--------|--------------|--------|--------|
|        | HR (95% CI) p | Q b    | HR (95% CI) p | HR (95% CI) p |
| Trp    | 0.83 (0.7–1.0) .10 .17 0.90 (0.7–1.2) .45 1.07 (0.9–1.3) .37 |
| Kyn    | 1.41 (1.1–1.9) .029* .051 0.99 (0.7–1.46) .98 0.99 (0.8–1.2) .98 |
| HK     | 1.77 (1.2–2.6) .005* .014* 0.91 (0.6–1.4) .68 1.31 (1.1–1.6) .004* |
| KA     | 0.90 (0.6–1.3) .58 .62 0.79 (0.6–1.1) .21 0.87 (0.7–1.0) .12 |
| XA     | 0.68 (0.7–1.2) .011* .025* 0.67 (0.5–0.9) .029* 0.83 (0.7–0.9) .037* |
| AA     | 1.07 (0.8–1.4) .58 .61 1.04 (0.8–1.4) .78 1.00 (0.9–1.2) .99 |
| HAA    | 1.14 (0.9–1.5) .28 .39 0.73 (0.5–1.0) .070 1.13 (1.0–1.3) .14 |
| QA     | 1.80 (1.1–2.9) .013* .028* 1.03 (0.8–1.4) .86 1.18 (1.0–1.4) .077 |
| KTR    | 1.55 (1.1–2.2) .009* .023* 1.01 (0.7–1.5) .96 0.98 (0.8–1.8) .85 |
| HK/XA  | 1.67 (1.3–2.2) <.001** .003* 1.31 (0.9–2.0) .19 1.40 (1.2–1.7) <.001** |

Risk factors for all-cause mortality assessed in patients with heart failure, and in controls with (CAD-C) and without (NCAD-C) coronary heart disease. Each metabolite in separate model.

Abbreviations: AA, anthranilic acid; CI, confidence interval; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; HK/XA, 3-hydroxykynurenine-xanthurenic acid ratio; HR, hazard ratio; KA, kynurenic acid; KTR, kynurenine-tryptophan ratio; Kyn, kynurenine; p, p-value; SD; standard deviation; Trp, tryptophan; Q, q-value, QA, quinolinic acid; XA, xanthurenic acid.

a Hazard ratio per 1 SD of the predictor by Cox proportional hazard analysis with all-cause mortality as the outcome, adjusted for age, gender, diabetes, current smoking, ejection fraction, estimated glomerular filtration rate, C-reactive protein, pyridoxal 5’phosphate and Trp (all metabolites in separate models. KTR not adjusted for Trp).
b p-value adjusted for multiple comparisons in the study (Benjamini-Hochberg; 0.05)

https://doi.org/10.1371/journal.pone.0227365.t003
Fig 3. 3-hydroxykynurenine, xanthurenic acid, quinolinic acid, the kynurenine-to-tryptophan ratio and survival. Predicted estimates from Cox regression with age, gender, current smoking, estimated glomerular filtration rate, diabetes mellitus, C-reactive protein and pyridoxal 5’phosphate as covariates. The analyses were performed in each group (HF, CAD-C and NCAD-C). The predicted estimates are shown at the mean level of each metabolite (black line), and 1 standard deviation above (red line) and below (blue line) the mean. Abbreviations: HF, heart failure; CAD-C, coronary artery disease controls; NCAD-C, non-coronary artery disease controls; HK, 3-hydroxykynurenic acid; XA, xanthurenic acid; QA, quinolinic acid; KTR, kynurenine to tryptophan ratio; SD, standard deviation.

https://doi.org/10.1371/journal.pone.0227365.g003
Discussion

The mKP Kyn, HK, and QA and derived ratios KTR and HK/XA were higher in heart failure patients compared to controls with or without CAD. HK, QA, KTR and the HK/XA ratio were associated with higher all-cause mortality in heart failure. XA was consistently associated with lower mortality in all groups.

Strengths of this study include a systematic evaluation of CAD and EF with coronary angiography and ventriculography at baseline, an adequate sample size and comprehensive assessment of metabolites. The results were adjusted for relevant confounders and multiple comparisons. Patients in the control groups underwent elective coronary angiography, and thus might not be considered a healthy population. However, they had no history of, or received no treatment for heart failure. All matching procedures are associated with some risk of selection bias which cannot fully be addressed by increasing the number of matching variables, due to the risk of overmatching. Further, mortality in the control groups were considerably lower than in the heart failure group, reducing the statistical power. Finally, we determined biomarkers only at baseline. Despite good-to-fair intra-class correlation coefficients of the included biomarkers (0.67 to 0.44) over a period of 38 months [28], repeated measures would have been informative.

Kyn levels in our study were higher in heart failure compared to both control groups. This is in line with previous findings [10]. Adding to prior studies, we found higher HK and QA, and the ratios KTR and HK/XA were also elevated in patients with heart failure. Notably, the same findings were observed compared to controls with or without CAD. Despite the association between heart failure and CAD, our findings indicated that heart failure itself is associated with these alterations in mKP, independent of CAD.

The mKP as predictors of HF did not improve diagnostic prediction in a clinically meaningful way as evaluated by AUC derived from ROC curves, and sensitivity and specificity from logistic regression. This study did not include known predictors (biomarkers) of HF, like N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and we could therefore not compare gold standard biomarkers with mKP, as predictors of HF. LVEF could have possibly been compared as a predictor of HF, but LVEF was included as a case definition parameter, generating spuriously high predictive value. However, as the KP is an essential and tightly regulated physiological pathway, it is unlikely that mKP concentrations will deviate so far from the norm that they can be used to clearly separate populations. As a further consequence of its key physiological role, it is likely to be affected by a range of human diseases. Even if mKP are likely poor diagnostic biomarkers, this does not preclude a role in the pathophysiology of heart failure.

Blood levels of pro-inflammatory mediators are elevated in heart failure [1]. This includes IFN-γ, an important inducer of IDO [5]. An in vitro study on monocytes exposed to IFN-γ identified that Kyn, KTR, HK, and QA were the most responsive to IFN-γ stimulation [29]. Furthermore, KTR is a marker of a cellular immune response, mainly reflecting monocyte activation [5]. The changes in circulating levels of mKP in heart failure observed in our data may thus reflect underlying monocyte activation, but might also related to reduced exercise in heart failure which can decrease clearance of mKP [30]. The changes in plasma KTR might also reflect increased TDO-activation and not only IDO-activation. Since this study does not include gene expression of TDO and IDO, dietary intake of Trp and hormone status, we cannot conclude that KTR represent only increased IDO-activation.

We observed associations between KTR, QA, and a trend for Kyn, and higher mortality in patients with heart failure. The control groups displayed attenuated, non-significant, effect sizes, perhaps indicating a vulnerability in patients with heart failure. Conceivably, myocardial
fibrosis, a key driver of disease progression in heart failure, could be related to monocyte production of mKP. Such a hypothesis could be assessed in experimental studies [31–33]. Our findings could be related to underlying chronic inflammation induced by IFN-γ. However, IFN-γ has not emerged as a key prognostic predictor in heart failure, and studies show diverging results [7]. One possible explanation for this discrepancy might be that baseline measurements of Trp and Kyn are better long-term markers of inflammation than cytokines, as they are considered more stable in individuals over time [28, 34]. As IDO activation, and the concentrations of Kyn, and Trp are immune-regulatory, the relationship with inflammation might be complex [35].

The HK/XA ratio was most significantly associated with mortality. This reflects the significant associations between HK and increased mortality and XA and lower mortality, where XA is the immediate metabolic product of HK. The associations between high HK and HK/XA ratio and mortality were also observed in patients with CAD, but with lower effect sizes. Low XA was associated with higher mortality in all groups. A similar relationship between the HK/XA ratio and mortality has been described in renal transplant recipients [36], showing that the association is not limited to patients with heart failure. In experimental studies, HK accelerates apoptosis and endothelial dysfunction in mice [37], and apoptosis in human cells [38, 39]. Of the mKP, XA is likely the most potent antioxidant [40]. The HK/XA ratio may reflect an imbalance between apoptotic stimuli and antioxidant capacity. This ratio has been established as a functional marker of vitamin B6 status, and an elevated HK/XA ratio may reflect reduced activity of the PLP-dependent enzyme KAT [41]. However, the results in this study were not confounded by PLP [41] levels, and PLP levels were not associated with mortality. KAT enzymes generating HK from XA also depend on α-keto acids, such as α-ketoglutarate [42], which we did not measure, but are unlikely to be rate limiting. The biological significance of this ratio in heart failure warrants future investigation.

The potential for anti-inflammatory therapy in cardiovascular disease has been highlighted with the successful trial targeting the interleukin-1β pathway in patients with established CAD [43]. Experimental studies, starting with animal models, are needed to understand if manipulation of the KP can be of benefit to patients with heart failure. Limitations to this study, that should be taken into account in future studies, include lack of repeated measures of mKP, as well as hormone-, and dietary status. Immune profiling, including measurements of cytokines and chemokines that can influence the KP, would also be beneficial. This study is an observational study and we can thus only conclude with associations between HF and mKP and not causal mechanisms. However, our study identifying mKP as prognostic markers, may indicate a future therapeutic potential.

**Conclusion**

In summary, we found that plasma levels of Kyn, HK, QA, and the ratios KTR and HK/XA are higher in heart failure compared to controls with or without CAD. Elevated plasma levels of HK and HK/XA were associated with increased mortality in both patients with heart failure and CAD, with larger effect size in patients with heart failure. QA and KTR were associated with increased mortality only in patients with heart failure. Low plasma levels of XA were associated with increased mortality in all groups. Our results indicate that future intervention on mKP may be of clinical interest.

**Supporting information**

S1 Table. Levels of tryptophan and kynurenines in cases and controls. Abbreviations: Trp, tryptophan; Kyn, kynurenine; HK, 3-hydroxykynurenine; KA, kynurenic acid; XA,
xanthurenic acid; AA, anthranilic acid; HAA, 3-hydroxyanthranilic acid; QA, quinolinic acid; KTR, kynurenine-tryptophan ratio; HK/XA, 3-hydroxykynurenine-xanthurenic acid ratio. 

Levels in median and (interquartile ranges). a Heart failure versus controls without coronary artery disease (NCAD-C, Mann-Whitney U test). b Heart failure versus controls with coronary artery disease (CAD-C, Mann-Whitney U test). * p-value < 0.05, ** p-value < 0.001.

**S1 Fig. Receiver operating characteristic (ROC) curves, HF versus NCAD-C.** ROC curves from unadjusted and adjusted multivariate logistic regression HF versus NCAD-C as outcome. Mod-1: regression with only the confounders diabetes, glomerular filtration rate, pyridoxal 5’phosphate and C-reactive protein included. Mod-2: mKP and ratios added to model. Abbreviations: AUC, area under curve; mKP, metabolites of the kynurenine pathway; Trp, tryptophan; Kyn, kynurenine; KTR, kynurenine-tryptophan ratio; HK/XA, 3-hydroxykynurenine-xanthurenic acid ratio.

**S2 Fig. Receiver operating characteristic (ROC) curves, HF versus CAD-C.** ROC curves from unadjusted and adjusted multivariate logistic regression HF versus CAD-C as outcome. Mod-1: regression with only the confounders diabetes, glomerular filtration rate, pyridoxal 5’phosphate and C-reactive protein included. Mod-2: mKP and ratios added to model. Abbreviations: AUC, area under curve; mKP, metabolites of the kynurenine pathway; Trp, tryptophan; Kyn, kynurenine; HK, 3-hydroxykynurenine; KTR, kynurenine-tryptophan ratio; HK/XA, 3-hydroxykynurenine-xanthurenic acid ratio.

**Acknowledgments**

We want to thank the recruiting study personnel and the staff performing the laboratory analyses at Bevital. We also thank the patients for their contribution.

**Author Contributions**

**Conceptualization:** Ottar Nygård, Lasse Melvaer Giil.

**Data curation:** Jan Erik Nordrehaug, Per Magne Ueland, Ottar Nygård.

**Formal analysis:** Anders Lund, Lasse Melvaer Giil.

**Project administration:** Jan Erik Nordrehaug, Per Magne Ueland, Ottar Nygård.

**Supervision:** Jan Erik Nordrehaug, Lasse Melvaer Giil.

**Writing – original draft:** Anders Lund, Jan Erik Nordrehaug, Lasse Melvaer Giil.

**Writing – review & editing:** Anders Lund, Jan Erik Nordrehaug, Grete Slettom, Stein-Erik Hafstad Solvang, Eva Kristine Ringdal Pedersen, Øivind Midttun, Arve Ulvik, Per Magne Ueland, Ottar Nygård, Lasse Melvaer Giil.

**References**

1. Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P. Inflammatory cytokines in heart failure: mediators and markers. Cardiology. 2012; 122(1):23–35. https://doi.org/10.1159/000338166 PMID: 22699305.

2. Sawyer DB. Oxidative stress in heart failure: what are we missing? Am J Med Sci. 2011; 342(2):120–4. https://doi.org/10.1097/MAJ.0b013e31822f9c0l PMID: 21747279.
3. Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure. Eur J Heart Fail. 2017; 19(11):1379–89. https://doi.org/10.1002/ejhf.942 PMID: 28891154.

4. Sager HB, Hulsmans M, Lavine KJ, Moreira MB, Heidt T, Courties G, et al. Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure. Circ Res. 2016; 119(7):853–64. https://doi.org/10.1161/CIRCRESAHA.116.309001 PMID: 2744755.

5. Ueland PM, McCann A, Midttun O, Ulvik A. Inflammation, vitamin B6 and related pathways. Mol Aspects Med. 2017; 53:10–27. https://doi.org/10.1016/j.mam.2016.08.001 PMID: 27593095.

6. Badawy AAB. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. International journal of tryptophan research: IJTR. 2017; 10:1177/1178646917691938. https://doi.org/10.1177/1178646917691938 PMID: 28469468.

7. Levick SP, Goldspink PH. Could interferon-gamma be a therapeutic target for treating heart failure? Heart Fail Rev. 2014; 19(2):227–36. https://doi.org/10.1007/s10741-013-9393-8 PMID: 23589353.

8. Zuo H, Ueland PM, Ulvik A, Eussen SJ, Vollset SE, Nygard O, et al. Plasma Biomarkers of Inflammation, the Kynurenine Pathway, and Risks of All-Cause, Cancer, and Cardiovascular Disease Mortality: The Hordaland Health Study. American journal of epidemiology. 2016; 183(4):249–58. https://doi.org/10.1093/aje/kwv242 PMID: 27444755.

9. Pedersen ER, Tuseth N, Eussen SJ, Ueland PM, Strand E, Svingen GF, et al. Association of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol. 2015; 35(2):455–62. https://doi.org/10.1161/ATVBAHA.114.304674 PMID: 25524770.

10. Konishi M, Ebner N, Springer J, Schevendor JC, Doehner W, Dschietzig TB, et al. Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure- Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Circ J. 2016; 81(1):52–61. https://doi.org/10.1253/circj.CJ-16-0791 PMID: 27904018.

11. Seccareccia F, Zuccaro P, Pacificti R, Meli P, Pannozzo F, Freeman KM, et al. Serum cotinine as a marker of environmental tobacco smoke exposure in epidemiological studies: the experience of the MATISS project. European journal of epidemiology. 2003; 18(6):487–92. Epub 2003/08/12. https://doi.org/10.1023/a:1024672522802 PMID: 12908713.

12. Pedersen AG, Ellingsen CL. Data quality in the Causes of Death Registry. Tidsskr Nor Laegeforen. 2015; 135(8):768–70. PMID: 25947599.

13. Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014; 33(6):1057–69. https://doi.org/10.1002/sim.6004 PMID: 24123228.

14. Midttun O, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid communications in mass spectrometry: RCM. 2009; 23(9):1371–9. Epub 2009/04/02. https://doi.org/10.1002/rcm.4013 PMID: 19337982.

15. Schafer JL. Analysis of incomplete multivariate data: Chapman and Hall/CRC; 1997.

16. Lee PH. Should we adjust for a confounder if empirical and theoretical criteria yield contradictory results? A simulation study. Sci Rep. 2014; 4:6085. https://doi.org/10.1038/srep06085 PMID: 25124526.

17. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004; 44(8):1587–92. Epub 2004/10/19. https://doi.org/10.1016/j.jacc.2004.06.072 PMID: 15489090.

18. Aquilani R, Opasich C, Verri M, Boschi F, Febo O, Pasini E, et al. Is nutritional intake adequate in chronic heart failure patients? J Am Coll Cardiol. 2003; 42(7):1218–23. Epub 2003/10/03. https://doi.org/10.1016/s0735-1097(03)00946-x PMID: 14522484.

19. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis. 2009; 204(1):309–14. https://doi.org/10.1016/j.atherosclerosis.2008.08.014 PMID: 18823890.

20. Theofylaktopoulou D, Midttun O, Ulvik A, Ueland PM, Tell GS, Vollset SE, et al. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clinical and experimental immunology. 2013; 173(1):121–30. Epub 2013/04/24. https://doi.org/10.1111/cei.12092 PMID: 23607223.

21. Young SN. Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects. J Psychiatry Neurosci. 2013; 38(5):294–305. https://doi.org/10.1503/jpn.120209 PMID: 23428157.

22. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov. 2002; 1(8):609–20. Epub 2002/10/31. https://doi.org/10.1038/nrd870 PMID: 12402501.
23. Parry HM, Deshmukh H, Levin D, Van Zuydam N, Elder DH, Morris AD, et al. Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus. Circ Heart Fail. 2015; 8(2):236–42. Epub 2015/01/07. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000920 PMID: 25561089.

24. Theofylaktopoulos D, Ulvik A, Midttun O, Ueland PM, Vollset SE, Nygard O, et al. Vitamins B2 and B6 as determinants of kynurenines and related markers of interferon-gamma-mediated immune activation in the community-based Hordaland Health Study. Br J Nutr. 2014; 112(7):1065–72. https://doi.org/10.1017/S0007114514001858 PMID: 25105221.

25. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005; 112(10):1428–34. https://doi.org/10.1161/CIRCULATIONAHA.104.508465 PMID: 16129801.

26. Wang Q, Liu D, Song P, Zou MH. Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci (Landmark Ed). 2015; 20:1116–43. Epub 2015/05/12. https://doi.org/10.2741/4363 PMID: 25961549.

27. Zuo H, Tell GS, Vollset SE, Ueland PM, Nygard O, Midttun O, et al. Interferon-gamma-induced inflammatory markers and the risk of cancer: the Hordaland Health Study. Cancer. 2014; 120(11):3370–7. Epub 2014/06/21. https://doi.org/10.1002/cncr.28869 PMID: 24948355.

28. Midttun O, Townsend MK, Nygard O, Tworoger SS, Brennan P, Johansson M, et al. Most blood biomarkers related to vitamin status, one-carbon metabolism, and the kynurenine pathway show adequate preanalytical stability and within-person reproducibility to allow assessment of exposure or nutritional status in healthy women and cardiovascular patients. J Nutr. 2014; 144(5):784–90. https://doi.org/10.3945/jn.113.169738 PMID: 24673988.

29. Jones SP, Franco NF, Varney B, Sundaram G, Brown DA, de Bie J, et al. Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease. PLOS One. 2015; 10(6):e0131389. https://doi.org/10.1371/journal.pone.0131389 PMID: 26114426.

30. Cervernka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health. Science. 2017; 357(6349). https://doi.org/10.1126/science.aaf7944 PMID: 28751584.

31. Hulsmans M, Sam F, Nahrendorf M. Monocyte and macrophage contributions to cardiac remodeling. J Mol Cell Cardiol. 2016; 93:149–55. https://doi.org/10.1016/j.yjmcc.2015.11.015 PMID: 26593722.

32. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013; 309(9):896–908. https://doi.org/10.1001/jama.2013.1963 PMID: 23462766.

33. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012; 60(14):1249–56. https://doi.org/10.1016/j.jacc.2012.04.053 PMID: 22395661.

34. Aziz N, Detels R, Quint JJ, Li Q, Gjertson D, Butch AW. Stability of cytokines, chemokines and soluble activation markers in unprocessed blood stored under different conditions. Cytokine. 2016; 84:17–24. Epub 2016/05/22. https://doi.org/10.1016/j.cyto.2016.05.010 PMID: 27208752.

35. Mandi Y, Vecsei L. The kynurenine system and immunoregulation. J Neural Transm (Vienna). 2012; 119(2):187–209. https://doi.org/10.1007/s00702-011-0681-y PMID: 21744051.

36. Minovic I, van der Veen A, van Faassen M, Riphagen IJ, van den Berg E, van der Ley C, et al. Functional vitamin B-6 status and long-term mortality in renal transplant recipients. Am J Clin Nutr. 2017; 106(6):1366–74. https://doi.org/10.1093/ajcn.117.164512 PMID: 28978540.

37. Wang Q, Zhang M, Ding Y, Wang Q, Zhang W, Song P, et al. Activation of NAD(P)H oxidase by tryptophan-derived 3-hydroxykynurenine accelerates endothelial apoptosis and dysfunction in vivo. Circ Res. 2014; 114(3):480–92. https://doi.org/10.1161/CIRCRESAHA.114.302113 PMID: 24261189.

38. Maliankot M, Nagaraj RH. Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human lens epithelial cells: apoptosis through the formation of 3-hydroxykynurenine. Int J Biochem Cell Biol. 2010; 42(9):1446–54. https://doi.org/10.1016/j.biocel.2010.04.014 PMID: 20435158.

39. Wei H, Leeds P, Chen RW, Wei W, Leng Y, Bredesen DE, et al. Neuronal apoptosis induced by pharmacological concentrations of 3-hydroxykynurenine: characterization and protection by dantrolene and Bcl-2 overexpression. J Neurochem. 2000; 75(1):81–90. https://doi.org/10.1046/j.1471-4159.2000.0750081.x PMID: 10854250.

40. Reyes Ocampo J, Lugo Huilron R, Gonzalez-Esquível D, Ugalde-Muniz P, Jimenez-Anguiano A, Pineda B, et al. Kynurenines with neuroactive and redox properties: relevance to aging and brain diseases. Oxid Med Cell Longev. 2014; 2014:646909. https://doi.org/10.1155/2014/646909 PMID: 24693337.

41. Ulvik A, Theofylaktopoulos D, Midttun O, Nygard O, Eussen SJ, Ueland PM. Substrate product ratios of enzymes in the kynurenine pathway measured in plasma as indicators of functional vitamin B-6 status. Am J Clin Nutr. 2013; 98(4):934–40. https://doi.org/10.3945/ajcn.113.064998 PMID: 24004893.
42. Han Q, Cai T, Tagle DA, Li J. Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci. 2010; 67(3):353–68. Epub 2009/10/15. https://doi.org/10.1007/s00018-009-0166-4 PMID: 19826765.

43. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12):1119–31. https://doi.org/10.1056/NEJMoa1707914 PMID: 28845751.